Effect of postoperative morbidity on long-term survival after hepatic resection for metastatic colorectal cancer

被引:187
作者
Ito, Hiromichi [1 ]
Are, Chandrakanth [1 ,2 ]
Gonen, Mithat [3 ]
D'Angelica, Michael [1 ]
DeMatteo, Ronald P. [1 ]
Kemeny, Nancy E. [4 ]
Fong, Yuman [1 ]
Blumgart, Leslie H. [1 ]
Jarnagin, William R. [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA
[2] Univ Nebraska Med Ctr, Div Surg Oncol, Dept Surg, Eppley Canc Ctr, Omaha, NE USA
[3] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA
[4] Mem Sloan Kettering Canc Ctr, Dept Med Oncol, New York, NY 10021 USA
关键词
D O I
10.1097/SLA.0b013e31816c405f
中图分类号
R61 [外科手术学];
学科分类号
摘要
Purpose: Resection is the most effective treatment for metastatic colorectal cancer (MCRC) to the liver. However, postoperative morbidity is common and its impact on long-term oncological outcome is unclear. The objective of this study was to evaluate the impact of postoperative morbidity on the long-term outcome after liver resection for MCRC. Methods: Medical records of patients who underwent liver resection for MCRC with curative intent between 1991 and 2002 were reviewed. Patients who died of postoperative complications were excluded; operative and perioperative data, including morbidity and clinicopathological variables, were analyzed. Patients were stratified by disease extent and risk of recurrence using a clinical risk scoring system. Results: A total of 1067 patients were included in the study and the median follow-up period was 41 months. The overall morbidity rate was 42%; the 5-year disease-specific survival (DSS) and overall disease-free survival (DFS) rates of patients who had complications were 41% and 25%, respectively, compared with 48% and 33%, respectively, for patients who did not have complications (P = 0.0059 for DSS, P = 0.0053 for DFS). On multivariate analysis, morbidity was not an independent predictor of either DSS or DFS; however, in a subgroup of patients with low clinical risk scores, morbidity was associated with a significant reduction in both DSS and DFS. Conclusions: Postoperative morbidity adversely affects long-term outcome after hepatic resection for MCRC in patients at lower risk for recurrence. Efforts aimed at reducing perioperative morbidity will not only reduce usage of resources but will likely further enhance the therapeutic benefit of resection for such patients.
引用
收藏
页码:994 / 1002
页数:9
相关论文
共 30 条
  • [1] Inflammation and cancer: back to Virchow?
    Balkwill, F
    Mantovani, A
    [J]. LANCET, 2001, 357 (9255) : 539 - 545
  • [2] COX DR, 1972, J R STAT SOC B, V34, P187
  • [3] de Melo GM, 2001, ARCH OTOLARYNGOL, V127, P828
  • [4] Hepatic resection in the United States - Indications, outcomes, and hospital procedural volumes from a nationally representative database
    Dimick, JB
    Cowan, JA
    Knol, JA
    Upchurch, GR
    [J]. ARCHIVES OF SURGERY, 2003, 138 (02) : 185 - 191
  • [5] Complications and costs after high-risk surgery: Where should we focus quality improvement initiatives?
    Dimick, JB
    Pronovost, PJ
    Cowan, JA
    Lipsett, PA
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2003, 196 (05) : 671 - 678
  • [6] Postoperative complication rates after hepatic resection in Maryland hospitals
    Dimick, JB
    Pronovost, PJ
    Cowan, JA
    Lipsett, PA
    [J]. ARCHIVES OF SURGERY, 2003, 138 (01) : 41 - 46
  • [7] Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer - Analysis of 1001 consecutive cases
    Fong, Y
    Fortner, J
    Sun, RL
    Brennan, MF
    Blumgart, LH
    [J]. ANNALS OF SURGERY, 1999, 230 (03) : 309 - 318
  • [8] Han SH, 2007, AM SURGEON, V73, P955
  • [9] Improvement in Perioperative outcome after hepatic resection - Analysis of 1,803 consecutive cases over the past decade
    Jamagin, WR
    Gonen, M
    Fong, YM
    DeMatteo, RP
    Ben-Porat, L
    Little, S
    Corvera, C
    Weber, S
    Blumgart, LH
    [J]. ANNALS OF SURGERY, 2002, 236 (04) : 397 - 407
  • [10] Jarnagin WR, 2001, CANCER, V91, P1121, DOI 10.1002/1097-0142(20010315)91:6<1121::AID-CNCR1108>3.0.CO